[go: up one dir, main page]

MX2009009119A - Metodo para tratar o prevenir la inflamacion sistemica. - Google Patents

Metodo para tratar o prevenir la inflamacion sistemica.

Info

Publication number
MX2009009119A
MX2009009119A MX2009009119A MX2009009119A MX2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A
Authority
MX
Mexico
Prior art keywords
treating
systemic inflammation
preventing systemic
subject
preventing
Prior art date
Application number
MX2009009119A
Other languages
English (en)
Inventor
Robert J Mcmahon
Josef Neu
Udo Herz
William Michael Russell
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of MX2009009119A publication Critical patent/MX2009009119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a un método nuevo para tratar o prevenir inflamación sistémica en un sujeto. El método administra al sujeto una cantidad terapéuticamente eficaz de LGG inactivado.
MX2009009119A 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica. MX2009009119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
MX2009009119A true MX2009009119A (es) 2009-09-04

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.
MX2009009119A MX2009009119A (es) 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.

Country Status (13)

Country Link
US (2) US9408819B2 (es)
EP (2) EP2114423B2 (es)
CN (3) CN101636172A (es)
AT (1) ATE544457T1 (es)
BR (2) BRPI0808145A2 (es)
CA (2) CA2679374C (es)
ES (2) ES2381232T3 (es)
MX (2) MX2009008875A (es)
MY (2) MY145769A (es)
PL (2) PL2124977T3 (es)
RU (2) RU2468807C2 (es)
TW (2) TWI418355B (es)
WO (2) WO2008106372A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
MX2009008875A (es) * 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.
AU2008333718B2 (en) * 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
RU2642301C9 (ru) * 2008-11-03 2018-06-27 Нестек С.А. Пробиотический бактериальный штамм для получения питательной композиции, улучшающей характер сна
ES2639364T3 (es) 2009-04-29 2017-10-26 Ganeden Biotech, Inc. Formulación de membrana celular bacteriana
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
BRPI1012849A2 (pt) 2009-05-11 2018-06-19 Nestec Sa lactobacillus johnsonii la1 ncc533 (cncm i-1225) e distúrbios imunes
BR112012017978A2 (pt) * 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
RU2593716C2 (ru) 2010-11-11 2016-08-10 Нестек С.А. Замороженные кондитерские изделия, содержащие пробиотические микроорганизмы
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
EP2455094A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) * 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
WO2013103826A1 (en) * 2012-01-06 2013-07-11 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP6643988B2 (ja) * 2013-08-09 2020-02-12 エービー−バイオティクス，エセ．ア． 乳児の過剰な泣きのためのプロバイオティクス
US20160303226A1 (en) * 2013-11-25 2016-10-20 Nestec S.A. Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations
RU2687038C1 (ru) * 2013-11-29 2019-05-06 Нестек С.А. Соответствующие возрастным потребностям питательные композиции с различным содержанием белка
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
TW202223083A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59308B1 (sr) 2015-06-15 2019-10-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EA038405B1 (ru) 2015-06-15 2021-08-24 4Д Фарма Рисёрч Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ШТАММЫ БАКТЕРИИ Bifidobacterium breve, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПАТОЛОГИЧЕСКОГО СОСТОЯНИЯ, ОПОСРЕДОВАННОГО IL-17 ИЛИ Th17
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3209310T (pt) 2015-11-20 2018-04-20 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
MA48939B1 (fr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
DK3600363T3 (da) 2017-06-14 2021-01-25 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
TW201919670A (zh) 2017-06-14 2019-06-01 英商4D製藥研究有限公司 包含細菌品系之組成物
CA3066557A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷
WO2024236053A1 (en) 2023-05-15 2024-11-21 Bactopharma Gmbh Treatment of cancer therapy-induced oral mucositis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) * 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
DE69819477D1 (de) * 1998-06-17 2003-12-11 Nestle Sa Mobile genetische Elemente als Werkzeuge zur genetischen Modifikation von L. delbrueckii oder L. helveticus
US6399055B1 (en) * 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
NZ512275A (en) * 1998-12-11 2003-11-28 Urex Biotech Inc Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
KR20040018319A (ko) * 2000-12-18 2004-03-03 프로비오헬쓰 엘엘씨 락토바실러스 카제이 균주 κε01에서 유래된 정장제 화합물
KR100419132B1 (ko) * 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
BR0207019A (pt) * 2001-02-06 2004-02-25 Nestle Sa Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
SI1565547T2 (sl) * 2002-06-28 2013-02-28 Biosearch S.A. Probiotiäśni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2004087178A1 (en) * 2003-03-31 2004-10-14 Alimentary Health Limited A formulation comprising a bacterial strain
PL1638415T3 (pl) * 2003-06-23 2011-05-31 Nestec Sa Preparat dla niemowląt lub preparat pochodny
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
EP1725662A4 (en) * 2004-03-15 2008-03-05 Tissugen Pty Ltd INFECTIOUS ETHIOLOGY OF A PROSTATE INFECTION AND METHOD OF IDENTIFYING CAUSE OF INJURY
ES2640212T3 (es) * 2005-04-08 2017-11-02 The Procter & Gamble Company Uso de bifidobacterias pro bióticas administradas por vía oral para obtener beneficios de belleza en seres humanos
EP1926395A1 (en) 2005-04-13 2008-06-04 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
MX2009008875A (es) * 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.

Also Published As

Publication number Publication date
WO2008106373A1 (en) 2008-09-04
HK1141729A1 (zh) 2010-11-19
CN105796607A (zh) 2016-07-27
RU2468807C2 (ru) 2012-12-10
RU2009135873A (ru) 2011-04-10
MY151892A (en) 2014-07-14
EP2124977B9 (en) 2012-05-02
EP2114423A1 (en) 2009-11-11
ES2381232T3 (es) 2012-05-24
BRPI0808145A2 (pt) 2021-03-23
BRPI0808052A2 (pt) 2014-06-24
TW200900075A (en) 2009-01-01
CA2679374A1 (en) 2008-09-04
CN101678053B (zh) 2015-12-16
EP2124977B1 (en) 2012-02-08
CN101636172A (zh) 2010-01-27
ATE544457T1 (de) 2012-02-15
US9408819B2 (en) 2016-08-09
TWI494114B (zh) 2015-08-01
CA2676956A1 (en) 2008-09-04
HK1136969A1 (en) 2010-07-16
ES2388198T3 (es) 2012-10-10
CA2676956C (en) 2017-06-13
TWI418355B (zh) 2013-12-11
RU2468808C2 (ru) 2012-12-10
RU2009135871A (ru) 2011-04-10
CA2679374C (en) 2016-05-31
EP2114423B1 (en) 2012-06-06
ES2388198T5 (es) 2020-07-14
US9408818B2 (en) 2016-08-09
PL2114423T3 (pl) 2012-10-31
EP2124977A1 (en) 2009-12-02
PL2124977T3 (pl) 2012-07-31
US20080206213A1 (en) 2008-08-28
WO2008106372A1 (en) 2008-09-04
TW200906426A (en) 2009-02-16
US20080206212A1 (en) 2008-08-28
CN101678053A (zh) 2010-03-24
EP2114423B2 (en) 2020-01-01
MY145769A (en) 2012-04-13
MX2009008875A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
MY145769A (en) Method for treating or preventing systemic inflammation
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
NZ596916A (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
WO2009079451A3 (en) Compositions and methods of promoting wound healing
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
PL2099769T3 (pl) Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych
WO2007100435A3 (en) Use of dha and ara in the preparation of a composition for the prevention or treatment of anemia
MY147175A (en) Method for preventing or treating the development of respiratory allergies
NZ588213A (en) Alpha-msh analogues for treating or preventing vitiligo
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
GB0710536D0 (en) Plant extract and its therapeutic use
CA2866819C (en) Method for treating inflammation
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights